Alkermes Buy Rating Affirmed: Profitability and Expansion in ...

Jan 29, 2024 · Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical …

CouponFollow Extension

$35.00
OFF

Buy Rating Affirmed On Alkermes’s Stock Amid Strong Earnings …

1 week from now

Jan 25, 2024 · Uy Ear, an analyst from Mizuho Securities, maintained the Buy rating on Alkermes (ALKS – Research Report). The associated price target is $35.00. The associated price target …

businessinsider.com

$32
OFF

Alkermes Plc (ALKS) Analyst Ratings - Stock Analysis

1 week from now

Oct 29, 2024 · A list of analyst ratings for Alkermes (ALKS) stock. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. ... Strong Buy. Maintains. $32 → …

stockanalysis.com

30%
OFF

Alkermes Jumped 30% In 3 Months; Big Profits - Investor's …

1 week from now

Oct 14, 2024 · The Relative Strength (RS) Rating for Alkermes moved up into a new percentile Monday, as it got a lift from 64 to 76. The upgraded 76% RS Rating shows that Alkermes …

investors.com

13%
OFF

Alkermes Stock Gets RS Rating Upgrade; Profits Surge

1 week from now

Feb 15, 2024 · Is Alkermes Stock A Buy? Alkermes stock surged 13% Thursday on positive Q4 and 2023 earnings results. The biotech stock is trying to complete a flat base with a 29.61 buy …

investors.com

$30
OFF

Alkermes Price Target Lowered To $30 From $32 At Goldman Sachs

1 week from now

Oct 25, 2024 · Goldman Sachs lowered the firm’s price target on Alkermes (ALKS) to $30 from $32 and keeps a Buy rating on the shares. The company’s Q3 results included operating …

nasdaq.com

$32.00
OFF

Alkermes Buy Rating Affirmed On Strong Commercial Performance …

1 week from now

May 2, 2024 · Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of $32.00....

businessinsider.com

17%
OFF

Alkermes Plc (ALKS) Statistics & Valuation Metrics - Stock Analysis

1 week from now

Sep 19, 2024 · Detailed statistics for Alkermes plc (ALKS) stock, including valuation metrics, financial numbers, share information and more. ... with operating and profit margins of 21.17% and 22.15%. Gross Margin : 83.17%: Operating Margin : 21.17%: ... which is 19.45% higher than the current price. The consensus rating is "Buy". Price Target : $35.00 ...

stockanalysis.com

30%
OFF

Alkermes Sees Relative Strength Rating Improve To 78

1 week from now

Aug 5, 2024 · Related news Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits. 10/14/2024 A Relative Strength Rating upgrade for Alkermes shows improving technical …

investors.com

$28
OFF

Alkermes Inc.: Strong Q3 Performance And Strategic Growth Drive …

1 week from now

Oct 27, 2024 · The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland. Read More on ALKS: Alkermes price target lowered to $28 from $29 at BofA. …

businessinsider.com

1%
OFF

4 Reasons To Consider Adding General Mills To Your Portfolio

1 week from now

Sep 9, 2024 · The company recently affirmed its fiscal full-year 2025 guidance of flat to 1% growth in organic sales and adjusted EPS between -1 and 1%. Its fiscal first quarter of 2025 earnings …

marketbeat.com

FAQs about Alkermes Buy Rating Affirmed: Profitability and Expansion in ... Coupon?

Should you buy Alkermes (AlkS) stock?

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ALKS stock, giving a Buy rating on January 23. Chris Shibutani has given a Buy rating for Alkermes based on a combination of factors, including the company’s transition into a standalone neuroscience business and its anticipated profitability in the upcoming fiscal years. ...

Is Alkermes a good stock to buy in 2025?

Furthermore, Alkermes is poised to maintain its EBITDA above $200 million in 2025, despite an anticipated decline due to reduced royalty and manufacturing revenues. The management’s commitment to maintaining profitability and their strategic share repurchase plans further bolster confidence in the stock’s long-term value. ...

Is Alkermes a risky company?

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. No risks detected for ALKS from our risk checks. Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly? ...

Why is Alkermes positioned for outperformance in the pharmaceutical sector?

Alkermes is positioned for outperformance in the pharmaceutical sector due to its conservative cash-heavy balance sheet and high-margin business model. The company focuses on therapies for alcohol dep... ...

Should you buy Alkermes (Alkermes)?

Chris Shibutani has assigned a Buy rating to Alkermes based on a triad of encouraging factors that underscore the company’s investment appeal. These factors include a clear path to profitability, a strategic approach to capital allocation, and forward momentum in their product pipeline. ...

Why has Joel Beatty rated Alkermes a buy?

Joel Beatty has given his Buy rating due to a combination of factors that highlight Alkermes’ potential for continued profitability despite some upcoming challenges. The company’s revenue for the third quarter was almost in line with expectations, driven largely by strong sales of Vivitrol. ...